The FDA last week approved Merck & Co.’s Keytruda for non-muscle-invasive bladder cancer, a rare form of the disease that does not respond well to other treatments. Keytruda is the first new approval in the space in more than 20 years. For the treatment of urothelial carcinoma, the most common form of bladder cancer, Keytruda is currently one of the most advantaged therapies on the market, holding preferred status for 10% of all covered lives in the pharmacy benefit, growing to 14% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 1/10/20